Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-O: Alpelisib + Olaparib in Platinum-Resistant/Refractory Ovarian Cancer
NCT04729387Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Countries
- 26
01
Overview
A Phase 3 trial of alpelisib in ovarian cancer, sponsored by Novartis. Started Jul 2021; status: terminated.
02
Drugs
alpelisib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04729387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729387.